17 April 2024
Incanthera
plc
("Incanthera" the
"Company")
Further re: Exercise of
Warrants
Incanthera plc (AQSE:INC),
the company specially focussed on
innovative technologies in dermatology and oncology, announces, it
has received further warrant exercise notices over 5,166,667
new ordinary shares in the Company, at an exercise
price of 10 pence per share (the "Warrant Shares"), providing the
Company with gross proceeds of £516,666.70. The
Company has also received notice of further warrant exercises over
258,333 new ordinary shares ("Further Warrant Shares") with
aggregate subscription proceeds of £25,833.30 which are expected to
be received shortly.
Following
the completion of the warrant exercises noted above and, in
conjunction with the warrant exercise announced on 9 April 2024,
the Company has received total warrant
exercises notices over 7,166,667 new ordinary shares in the Company
providing it with gross proceeds of £716,667.
Admission
Application has been made for the
Warrant Shares to be admitted to trading on the Aquis Stock
Exchange Growth Market on or around 19 April
2024 ("Admission") and will rank pari passu with the ordinary shares of
the Company in issue.
Application for the Admission of the
Further Warrant Shares will be made following the receipt of
cleared funds. The Company will update the market in due
course.
Total Voting Rights
Following Admission, the Company's
issued share capital will comprise 99,018,214 ordinary shares of 2 pence
each, with each share carrying the right to one vote, therefore the
total number of voting rights in the Company will be
99,018,214 .
This figure may be used by shareholders as the
denominator for calculations by which they will determine if they
are required to notify their interest in the Company, or a change
to their interest in the Company, under the Financial Conduct
Authority's Disclosure Guidance and Transparency Rules.
Commenting on the conclusion of the
Warrants Exercise, Chairman, Tim McCarthy said:
"We are delighted with the
positive response of the warrant exercise.
"These warrants were originally
issued as part of a fund raising in 2021, and this strong take up
demonstrates the confidence shown by many long-standing loyal
shareholders in the Company's future prospects and the management's
strategy. This further strengthens the Company's cash position as
we prepare for the launch of our luxury skincare range Skin +
CELL.
"We look forward to providing
further updates as our progression continues."
The
Directors of Incanthera are responsible for the contents of this
announcement.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014 (which forms part of
domestic UK law pursuant to the European Union (Withdrawal) Act
2018).
For further information please
contact:
Notes to Editors
About Incanthera plc
Incanthera is a specialist company
focused on innovative technologies in dermatology and
oncology. It seeks to identify and develop innovative solutions to
current clinical, commercially relevant unmet needs, utilising new
technology from leading specialists and academic institutions as
well as its in-house development team.
The Company originated from
the Institute of Cancer Therapeutics ("ICT") at
the University of Bradford. Incanthera's strategy
is to develop each candidate in its portfolio from initial
acquisition or discovery to securing its future through
commercially valuable partnerships at the earliest opportunity in
its development pathway.
For more information on the Company
please visit: www.incanthera.com
@incantheraplc
About Skin + CELL
Skin + CELL is Incanthera's luxury
skincare brand utilising our ground-breaking formulation and
delivery expertise, to bring scientifically proven formulations to
cosmetics. Skin + CELL's unique formulations, enriched with
targeted bioactive B3 (an activated form of niacinamide) are
delivered directly into the skin's cells to optimise and protect
cellular health, energy and protective capabilities.
Incanthera's skincare technology
harnesses unique delivery pathways through recently patented
formulations designed by our in-house experts who have previously
formulated skincare for some of the world's leading skincare and
pharmaceutical companies. These formulations fortify otherwise
depleted physiological pathways to improve the skin's performance,
ability to self-repair and to address previously unmet cosmetic
conditions in skin health.
•
Skin + CELL's unique formulations, currently enriched with targeted bioactive B3 (an activated
form of niacinamide) but anticipating further bioactive ingredient
formulations are delivered directly into the skin's cells to
optimise cellular health, energy and protective
capabilities.
•
Independent studies have shown Incanthera's
technology is uniquely effective in delivering Bioactive B3 below
the dermal barrier, energising the living cells of the skin to
maintain natural health and protection against adverse
environmental challenges and maintaining even skin
tones.
•
Skin + CELL's complementary range of products are
based on advanced, clinically designed, formulation concentrates
which combine leading edge pharmaceutical enhancement technology
with selected prestige cosmetic ingredients to give an effective
product which gives a silky emollience in use and leaves the skin
visibly radiant, energised and protected.
Skin + CELL's luxury skincare
current range extends across face, body, hand, face serum and eye
serum, and will also include SPF concentrations and further
bioactive derivatives of vitamins in the future.
About Marionnaud
Marionnaud is the largest luxury
perfumery and cosmetics chain in Europe with over 1,220 stores and
a 27% market share in France. Marionnaud is managed by the AS
Watson Group based in Hong Kong, the world's largest international
health and beauty retailer.
https://www.marionnaud.com
About A.S. Watson
The A.S. Watson Group is the
world's largest international health and beauty retailer, with
16,100 stores in 28 markets, primarily in Asia and Europe. A
member of CK Hutchison Holdings, A.S. Watson operates the world's
largest portfolio of retail formats, retail brands and has the
largest geographical presence including a significant online retail
presence.
http://www.aswatson.com/
https://youtu.be/IZ6TolZi4Go